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ASSESSMENT OF THE STIMULUS PROPERTIES OF MDA AND MDMA
STEREOISOMERS IN A LSD-SALINE-AMPHETAMINE
DISCRIMINATION
Michele Marie Taylor, M.A.
Western Michigan University, 1996
This study employed a three-choice drug discrimination procedure in order to
further delineate the discriminative stimulus properties of the stereoisomers of 3,4methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine
(MDMA). Eight male Sprague-Dawley rats were trained to discriminate amphetamine

(1.0 mg/kg) and LSD (.08 mg/kg) from saline in a three-lever, food reinforced
(sweetened condensed milk) drug discrimination procedure. A fixed-ratio (FR) 20
schedule with a reset condition for incorrect responses was employed. When criteria
(85% over 10 consecutive sessions) were met, (+)-MDA, (-)-MDA, (+)-MDMA
(.31, .63, 1.25 mg/kg) and (-)-MDMA (.88, 1.75, 3.5 mg/kg) were tested for
substitution. All of these compounds produced a greater percentage of responding on
the LSD lever than on the amphetamine lever. These results suggest that the
discriminative stimulus properties of both MDMA and MDA isomers resemble those
of LSD more closely than those of amphetamine. It is suggested that the use of a
three-lever discrimination procedure affords a greater degree of precision than the
traditional two-level assay in the assessment of the complex stimulus properties of
these designer drugs.
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CHAPTER I
INTRODUCTION
The History of MDMA
Ecstasy, often called 'E', 'ADAM' or 'XTC' is known chemically as 3,4-methylene
dioxymethamphetamine (MDMA). MDMA, a phenylisopropylamine, is a structural ana
log of amphetamine. It is also chemically related to the psychedelic drug 3,4-methyl
enedioxyamphetamine (MDA or the "love drug"). By adding a methyl group to MDA,
the "kitchen chemists" of the late 1960s wanted to produce a new drug w�Jh the effects
of:'its parent but of shorter duration. However, MDMA is not a new drug. It was first
synthesized by Merck, a German pharmaceutical firm in Darmstadt Germany in 1912
(Bt!ck & Rosenbaum, 1994) and patented in 1914 (McDowell & Kleber, 1994).
"MDMA was not, as is sometimes believed, initially intended as an appetite suppressant,
but was originally developed as a parent compound" (McDowell & Kleber, 1994, p. 127).
When the anorectic effects of the drug were discovered, it was proposed as an appetite
supprnssant for soldiers during the First World War (Redhead, 1993). However, it never
achieved clinical applicability for this indication. The United States Army experimented
with the compound during the 1950s. Since the obtained information was made public
in the early 1970's interest in the compound waned for many years.
"MDMA was first used recreationally by humans in the late 1960s" (McDowell
1
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& Kleber, 1994, p. 127). It was "discovered" by New Age seekers who valued its capac
ity to induce feelings of well-being and connection to others. Beginning in 1976, a small
number of therapists on both coasts began to utilize MDMA for similar reasons. MDMA
was believed to be beneficial as a therapeutic adjunct on the predication that it facilitated
communication, acceptance, and disinhibition. Shulgin and Shulgin (1991) recount the
story of a psychologist they named "Adam," who is purportedly the "father" of MDMA
use as an adjunct to psychotherapy. Despite their belief in MDMA's efficacy, therapists
were reluctant to publish any preliminary findings, fearing that such efforts would only
hasten the criminalization ofthe then legal drug and block further research (Eisner, 1989;
Seymour, 1986). It was not until the late 1970s that the first published pharmacological
investigation ofMDMA in humans appeared. Shulgin and Nichols (1978) described how
MDMA evoked an easily controlled altered state of consciousness, with emotional and
sensual overtones. These properties made it promising to therapists and tempting, even
tually, to the curious public as well (Shulgin & Nichols, 1978). The ongoing therapeutic
use remained unknown to much of the public with the exception of a slowly burgeoning
population of recreational users. Then, when distribution patterns changed and the media
discovered the drug in the mid 1980s, the recreational market proliferated.
The Emergence of the Contemporary Psychedelic Subculture
The recreational market for MDMA slowly expanded in the early 1980s. This was
a period during which a group of chemists in the Boston area, called the "Boston Group,"
had commenced production in 1976 (Beck & Rosenbaum, 1994). In anticipation of
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enjoying greater profits by expanding efforts to meet ever increasing demands for
MOMA, the Southwest distributor for the Boston Group put together his own operation
with the financial backing of some friends from Texas (Beck & Rosenbaum, 1994). As
Beck and Rosenbaum (1994) described:
The "Texas Group" quickly became the largest and most intrepid MOMA distri
bution network in the nation. The Texas distributors used blatant promotional
tactics, circulating posters announcing "Ecstasy parties" at bars and discos with
MOMA billed as a "fun drug" which was "good to dance to." Interestingly, the
drug was available over the counter at bars and convenience stores. Such billing
appealed to young adults (p. 19).
"For this group, the drug's capacity to induce feelings of connection, as well as a psycho
motor agitation that can be pleasurably relieved by dancing, make it an ideal party drug"
(McDowell & Kleber, 1995, p. 128). Not surprisingly, recreational use of the drug at
dance clubs exploded. Recently, MOMAs popularity has been inextricably linked with
the rise of the rave phenomenon. "Raves" are all-night dance marathon parties popular
in England since the 1980s, which have found their way to the United States and the rest
of the world (McDowell & Kleber, 1995). The recreational use of MOMA at all-night
"raves" has been implicated in a number of deaths in Britain. It has been postulated
(Randall, 1992) that the reported deaths were associated with the setting at such "raves."
For instance, the crowded conditions, high temperature and loud noise may have
enhanced the toxicity of the drug. Further, dehydration has been implicated as a variable
which may modulate the toxicity of MOMA (Green, 1995). Indeed, on a hot day in the
summer of 1992 a number of deaths, as many as 15, were correlated with the use of
MOMA in clubs-which had turned off their water supplies in an effort to maximize profits
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by selling bottled water (McDowell & Kleber, 1995). According to the British National
Poisons unit, the fatalities were the result ofa form ofheatstroke, caused by the effects
ofMDMA which were intensified by dehydration and prolonged, vigorous dancing in hot,
stifling settings. The English government has since mandated a continuous water supply
at all clubs. Concomitantly, the reports ofMDMA rel�t.ed deaths had stopped. These
alarming reports coupled with the considerable literature regarding the long-term
neurotoxic effects (Ricaurte et al., 1985; Schmidt et al., 1986) ofthe drug prompted the
campaign to criminalize MDMA.
The Criminalization ofMDMA
The rampant use of MDMA attracted the attention of Texas Senator Lloyd
Bentsen. He petitioned the Food and Drug Administration and the compound was placed
in Schedule I ofthe Controlled Substances Act on an emergency basis on July 1, 1985
(McDowell & Kleber, 1994, p. 128). This occurred prior to the previously scheduled
series of hearings which were intended to determine MDMA's permanent status. The
Schedule I status is restricted for those drugs which lack currently acceptable medical
utility and have a high abuse potential. "DEA officials were reportedly surprised that a
substantial number ofpeople, including therapists and clergymen, supported a less restric
tive categorization" (McDowell & Kleber, 1994, p. 128). Nevertheless, the drug was
permanently placed in Schedule I. This was followed by the synthesis and distribution
of 3, 4-methylenedioxyethamphetamine, (MDE or Eve) a structural analog ofMDMA.
"Shortly after attempts to market Eve, Congress passed the Controlled Substances

5
Analog Act in 1986 (Designer Drug bill or CSAA) outlawing all new analogues of illicit
drugs" (Beck & Rosenbaum, 1994). Designer drugs are variations of already federally
regulated compounds which are designed to mimic the effects of the compounds from
which they were derived. Prior to the enactment of the CSAA, chemists and drug dealers
hastily synthesized analogs of already scheduled drugs thereby evading the Food and
Drug Administration's list of restricted drugs. Hence, they were marketing an essentially
legal drug. The hurried mass production of these analogs increased the risk of distribut
ing a potentially hazardous compound since no systematically controlled experimental
analysis occurred. The well-intentioned enactment of the CSAA did not eliminate the
inevitable "grace period" between the synthesis and distribution of a novel analog and the
federal control of that compound. Further, the abuse of these high-technology creations
will likely continue, because such drugs are relatively inexpensive to produce and pharm
acologically superior (more potent) than other illicit drugs (Carroll, 1993). Still, the
behavioral and physiological effects of such compounds are virtually unknown preceding
the distribution of them to many users.

Generally, the effects of potentially hazardous

compounds have occurred before the appropriate actions could be taken to inform users
of such deleterious side-effects. "Without any quality control, designer drugs are often
sold on the street contaminated with impurities and poisonous by-products" (Carroll,
1993, p. 21).

For instance, the synthetic opiate l-methyl-4-phenyl-1,2,3,6-

tetrahydropyridine (MPTP) has been known to cause substantial damage to the substantia
nigra resulting in swift and severe Parkinsonian-like symptoms (Langston & Palfreman,
1995). Likewise, MDMA has also been purported to produce untoward physiological
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effects. While there is a considerable amount of published reports regarding the
physiological effects of MOMA, its exact mechanism of action are yet unknown. Thus,
further examination of the effects of MOMA is a noteworthy pursuit.
The Neurochemical and Physiological Effects of MOMA
Piercey et al (1990) examined the effect of MOMA on neuronal firing rates and
reported that high doses of MOMA potently depressed the firing rates of a subpopulation
of serotonin neurons in the dorsal and median raphe and that dopamine neurons were
unaffected, suggesting that MOMAs distinct effects are mediated through a subpop
ulation of serotonergic neurons. Neurochemical investigations have demonstrated that
MOMA and its demethylated metabolite, MOA induce the presynaptic release of seroto
nin (5-HT) and dopamine (DA) (Johnson et al., 1986; McKenna et al., 1991; Yamamoto
& Spanos, 1988). Several analyses of the individual isomers of these compounds have
revealed that the (+)-isomers are more potent DA releasers than the (-)-isomers
(Hiramatsu & Cho, 1990; Johnson et al., 1986; McKenna et al., 1991) and the (-)-isomers
bind to 5-HL receptors with higher affinity than the (+)-isomers (Lyon et al., 1986).
Behavioral studies also indicate that (+)-MOMA is more potent than (-)-MOMA in
disrupting operant responses (Rosecrans and Glennon, 1987) and causing stereotypy in
rats (Hiramatsu et al., 1989).
The neurochemical, behavioral and physiological evidence indicate that the (+)
isomers of MOA and MOMA are more closely related to amphetamine, a potent DA
releaser that also produces stereotypy, at sufficient doses, in rats. Further, the
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stereoisomers ofMDA and MDMA have been demonstrated to differ in the extent to
which they produce stimulus generalization in subjects trained to discriminate between
either amphetamine or a hallucinogen and a vehicle. For instance, (+)-MDA substitutes
for amphetamine (Glennon & Young, 1984) and (-)-MDA substitutes for the hallucino
gens 2,5-dimethoxy-4-methylphenylisopropylamine (DOM) (Glennon et al., 1982) and
d-lysergic acid diethylamide (LSD) (Callahan & Appel, 1988). Although neither isomer
ofMDMA was found to substitute for DOM (Glennon et al., 1982) or LSD (Callahan
& Appel, 1988), it has been reported (Glennon et al., 1988) that (+)-MDMA substitutes
for amphetamine but (-)-MDMA does not. On the other hand, Oberlender and Nichols
(1988) found that neither isomer ofMDMA substitutes for amphetamine. Broadbent et
al. (1992) reported that only (-)-MDA substitutes for LSD. In subjects trained to dis
criminate the individual isomers ofMDA or MDMA (Baker et al., 1995; Broadbent et
al., 1992), mescaline does not produce stimulus generalization while LSD substitutes for
(-)-MDMA and both isomers ofMDA. Such inconsistencies among the reported results
seem to indicate that the extent to which the discriminative stimulus effects ofthe optical
isomers ofboth MDMA and MDA are amphetamine- or hallucinogen-like depends on the
training drug and the discrimination procedures utilized.
Purpose ofthe Present Study
This procedure is a modification ofthe traditional two-lever drug discrimination
assay which provides an assessment of the subjective, interoceptive stimulus properties
of a range of drugs. Subjects are trained to discriminate one interoceptive stimulus
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(drug) from another (vehicle). This paradigm is useful in the classification of novel
compounds. It can be used to provide indirect information regarding underlying neuro
chemical events. In order to further delineate the discriminative stimulus properties of
the stereoisomers of both MDA and MDMA, a three-choice drug discrimination proce
dure was employed. Employing a three-choice drug discrimination procedure in which
subjects are trained to discriminate between two distinct drugs may further delineate the
discriminative stimulus properties of the stereoisomers ofMDA and MDMA.

CHAPTER II
METHODS
Subjects
Eight male Sprague-Dawley rats, maintained at 85% of their free-feeding weights,
were used as subjects. The subjects were approximately eight months old at the begin
ning of the study. The subjects were exposed to operant conditioning procedures as part
of an undergraduate learning lab prior to the initiation of the present study. The subjects
were individually housed in hanging wire mesh cages. Water was provided ad libitum.
The subjects were housed in a room with controlled lighting (12-hr light/12-hr dark) and
temperature (20-22° C).
Apparatus
Eight operant conditioning chambers (Med Associates, East Fairfield, VT) mea
suring 28 cm long, 21 cm wide, and 21 cm high, were used. The front (21 X 21 cm) wall
of each chamber was equipped with three response levers centered horizontally 7 cm
above the floor. A dipper through which 0.1 ml sweetened condensed milk (diluted with
tap water at a 1 :2 ratio) was delivered was centered 5 cm below the levers. An exhaust
fan provided masking noise and ventilation. The minimum force requirement for opera
tion of a lever was 14 g. The top of the operant chambers were constructed of clear
9
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plexiglass and the work panel and back wall were made of aluminum. Ambient illumi
nation was supplied by a 7-watt light (houselight) centrally located on the top of the work
panel. Control of the experimental events and data recording was accomplished through
the use of a Zenith Z-320/SX microcomputer (IBM compatible) using software and an
interface designed by Med Associates (East Fairfield, VT).
Drugs
LSD, DOM, d-amphetamine as well as the stereoisomers of MDMA and MDA
were obtained from the National Institute on Drug Abuse (Rockville, MD). The doses
were expressed as the salt. The drugs were dissolved in 85% physiological saline and
were administered by intraperitoneal injection (i.p.).
Training
The subjects were trained to discriminate amphetamine (1.0 mg/kg) and LSD (.08
mg/kg) from saline in a three-choice drug discrimination procedure under a fixed-ratio
20 (FR 20) schedule of reinforcement. All eight subjects were reinforced for responses
on the center lever following saline injections. Four of the subjects were reinforced for
responses on the right lever following injections of amphetamine and on the left lever fol
lowing injections of LSD. The conditions were reversed for the remaining subjects. The
drug and saline injections were administered 15 min. prior to 20 min. training sessions.
The training sessions were conducted six days per week (Mon.-Sat.).
Training began under a FR 1 schedule. When responding was consistent and
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stable, the FR was incremented gradually from 1 to 20. Reinforcement was contingent
upon 20 consecutive responses on the correct lever. Incorrect responses on either lever
reset the response counter. A semi-random schedule of drug administration was
employed in order to ensure equitable presentation of all conditions. The percent of
correct lever choice prior to the first reinforcer of·each training session was used to
determine discrimination acquisition.

This ensured that responding was stimulus

controlled and not contingency controlled.
Testing
When each subject achieved a mean of at least 85% correct lever choice over a
period of 10 consecutive training sessions, substitution tests began. Dose response deter
minations were generated for the training drugs amphetamine (.25, .5, 1.0, 2.0 mg/kg)
and LSD (.02, .04, .08, .16 mg/kg). Vehicle control tests were also determined. (+)
MDA, (-)-MDA, (+)-MDMA (.31, .63, 1.25 mg/kg) and (-)-MDMA (.88, 1.75, 3.5
mg/kg) were tested for substitution. These doses were chosen on the basis of previous
studies (Baker et al., 1995; Broadbent et al., 1992) in which subjects were trained to dis
criminate each of the isomers. DOM (.5, 1.0, 1.5 mg/kg) and cocaine (1.25, 2.5, 5.0,
10.0, 15.0 mg/kg) were also tested for substitution. The order of dose presentation was
counter balanced within and between subjects. The substitution tests were conducted
under extinction and concluded once 20 consecutive responses were emitted on either
lever or 20 minutes elapsed, whichever occurred first.

CHAPTER III
RESULTS
For each dose tested, the mean percent oftotal responses on each lever was calcu
lated and plotted for visual analysis. Complete generalization was defined as a mean of
at least 80% of the total responses on any particular lever. Partial generalization was de
fined as a mean between 50% and 80% of the total responses on any particular lever. A
two-factor repeated measures analysis of variance (ANOVA) was conducted for the LSD
and amphetamine levers during substitution tests with the optical isomers ofl\IDA and
l\IDMA. The two factors were isomer and dose (3 dose levels and vehicle control). For
substitution tests with LSD, DOM, amphetamine and cocaine, the percent of total
responses on either the amphetamine or LSD lever was analyzed using a one-factor
repeated measure ANOVA. Response rate (responses per second) during substitution
tests was also calculated, plotted and statistically analyzed using a one-factor repeated
measures ANOVA.
Each of the eight subjects' behavior came under stimulus control of all three
drug conditions. The discrimination criterion (individual means of at least 85 % cor
rect lever choice prior to the delivery of the first reinforcer over 10 consecutive train
ing sessions) was met in all eight subjects within an average of 100 training sessions.
Each of the eight subjects completed substitution tests with three doses of the
12
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optical isomers of MDA and MDMA. Further, each subject completed dose response
tests with the two training drugs. Vehicle control tests were completed by each of the
subjects. Since the order of the substitution tests was random, the condition received
prior to any particular test session was not the same for each subject. When LSD con
trol tests were conducted, the condition each subject received during the previous ses
sion appeared to modulate the obtained results. For instance, the two subjects for
which LSD control tests followed LSD training sessions, the mean percent of LSD
appropriate responses was much lower than the subjects which received amphetamine
or saline during the preceding session. Each of these two subjects emitted 100% of
their responses on the saline-appropriate lever. To eliminate acute tolerance as a var
iable, LSD control tests were conducted following each of the three conditions. The
resultant control values plotted are a mean of all three tests. The group mean was
92% following amphetamine training sessions (N=8). Following saline sessions, the
mean was 76% (N=8). The mean was only 53% following LSD training sessions
(N=7). Figure 1 shows the dose response curves for the training drugs. LSD pro
duced dose dependent increases in LSD-appropriate responding (Figure 1, Graph A).
The training dose produced 81% LSD-appropriate responding. LSD (.16 mg/kg) was
also tested for substitution and it produced 60% LSD-appropriate responding. A one
factor repeated measures ANOVA on percent LSD-lever responding revealed a signif
icant dose effect (F4,3s = 4. 74, p < .05). A one factor repeated measures ANOV A
on LSD response rate revealed a nonsignificant dose effect (FJ,21 = .73, p > .05).
Figure 1 also depicts the dose response curve for amphetamine (Figure 1, Graph B).
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A mean of 82% was obtained when the training dose of amphetamine ( 1.0 mg/kg) was
tested. Amphetamine (2.0 mg/kg) (not shown) was also tested but diminished
responding greatly. Most of the subjects did not complete the FR20 requirement. A
one-factor repeated measures ANOVA on percent amphetamine-lever responding
revealed a significant effect of dose (F3,21 = 20.01, p < .01). Figure 1 (Graph D)
depicts a significant decrease in response rate during amphetamine tests compared to
saline control (F3,21

= 7.98, p

< .01).

To affirm that the subjective effects of the two distinct drugs had been estab
lished as discriminative stimuli, DOM and cocaine were tested for stimulus generaliza
tion. Figure 2 depicts the dose response functions for both DOM and cocaine. Figure
2 (Graph A) shows percent total responses for DOM. Visual analysis of the graph
reveals that DOM produced dose dependent increases in LSD-appropriate responding.
An overall mean of 87% was obtained at the highest dose tested. DOM was tested in
seven of the eight subjects. A one-factor repeated measures ANOVA revealed a
significant dose effect (F3,1s = 9.8, p < .01) but a nonsignificant effect on rate (F2,12

= .20, p

> .10).

Figure 2 (Graph B) shows overall percent for cocaine. Initially, cocaine (2.5,
5.0 and 10.0 mg/kg) was tested for substitution. Since little variation in amphetamine
appropriate responding occurred (81%, 80%, and 83% respectively) cocaine 1.25 and
15.0 mg/kg) was also tested. All of the subjects (N = 5) emitted at least 90% of their
responses on the amphetamine lever at the highest dose tested (overall mean 96%).
A one-factor repeated measures ANOVA revealed a significant dose effect (Fs,20 =
9.0, p < .01) as well as a significant effect on rate (F4,16 = 2.4, p < .05).
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Figures 3 and 4 show the dose response curves for the stereoisomers of MDA
and MDMA. Visual inspection of the dose effect curves reveals that the optical iso
mers of both MDA and MDMA do not substitute for amphetamine. In fact, both(+)
and(-)-MDMA and(-)-MDA produced virtually no responding on the amphetamine
lever. (+)-MDA(.63 mg/kg) engendered the greatest degree of amphetamine lever
responding. Two of the eight subjects emitted 100% of their responses on the
amphetamine-appropriate lever, while three others emitted 100% of their responses
on the LSD-appropriate lever. The remaining subjects emitted 100% of their re
sponses on the saline lever. (+)-MDA (.63 mg/kg) produced partial generalization
of the subjects responding to the LSD-appropriate lever (66% ) . In contrast, all of the
subjects allocated less than 5% of their responses on the amphetamine lever with(+)
and (-)- MDMA and (-)-MDA. While (+)-MDMA (1.25 mg/kg) produced the
greatest amount of LSD-appropriate responding(71% of the responses occurred on the
LSD lever). (-)-MDMA (1.25 mg/kg) produced nearly equal responding on the
saline- and LSD-appropriate levers while the subjects emitted less than 2% of their
overall responding on the amphetamine lever. Further, (-)-MDMA produced dose
dependent increases in LSD lever responses. (-)-MDMA also produced equitable
responding on both the LSD and saline levers while all of the subjects emitted less
than 2% of their responses on the amphetamine-appropriate lever.
A two-factor repeated measures ANOVA on percent LSD-lever responses fol
lowing(+)- and(-)-MDMA tests revealed a significant dose effect (F3,s6 = 5.9, p
.01) but no effect of isomers {F3,56 = 1.4, p

>

<

.05) compared to saline control
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values. A significant dose effect on response rate following
tained (F2,14

= 9.4, p

(-)-MOMA was ob

< .01). A two-factor repeated measures ANOVA on percent

LSD-lever and amphetamine-lever responses following (+)- and (-)-MOA tests was
also conducted. There was not a significant effect of dose or isomer. However, there
was a significant dose effect on response rate following (+)-MOA compared to vehi
cle control values. In addition, the results of the ANOVA revealed a nonsignificant
dose and isomer effect on amphetamine-lever responding.
Since the optical isomers of both MDA and MDMA produced only partial gen
eralization to LSD, one higher dose was tested for each isomer of both drugs. (+)
MDA, (-)-MDA, (+)-MDMA (2.5 mg/kg) and (-)-MOMA (5.0 mg/kg) were tested.
(-)-MOMA (5.0 mg/kg) was behaviorally disruptive. The subjects laid flat on their
stomachs and emitted very few responses. (+)-MOMA (2.5 mg/kg) also disrupted
behavior. Another noted indication at this dose was clear fluid dripping from the
mouth and nose. Such symptomotology implicates the 5-HT system. (+)-MOA (2.5
mg/kg) produced similar behaviors and symptoms. Conversely, (-)-MOA (2.5 mg/kg)
did not disrupt responding and partially substituted for LSD. The obtained mean was
78%.

CHAPTERIV

DISCUSSION
The present study clearly demonstrates that rats can be trained to differentially
respond to the subjective effects of both a hallucinogen and a stimulant in a three
choice drug discrimination assay. Thus, both amphetamine and LSD were serving as
discriminative stimuli which controlled each subject's responding. The number of
training sessions required to reach the discrimination criteria was approximately four
times longer than is generally required in the traditional two-lever drug discrimination
procedures employing either LSD (Callahan & Appel, 1988) or amphetamine
(Glennon & Young, 1984). The results of the present study suggest that the discrimi
native stimulus properties of the stereoisomers of both MDA and MDMA are dissimi
lar to those of amphetamine. This is inconsistent with previous reports in which (+)
MDA and ( + )-MDMA substitute for amphetamine (Glennon & Young, 1984;
Glennon et al., 1988). Conversely, in subjects trained to discriminate between the
optical isomers of MDA (Broadbent et., 1992) or MDMA (Baker et al., 1995) from,
saline, amphetamine did not completely substitute for any of these compounds.
Further, the results suggest that the optical isomers of MDA and MDMA are
more similar to LSD than to amphetamine. The observation that the (+)-isomers of
both MDA and MDMA produced a considerable amount of LSD-appropriate
21
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responding is inconsistent with neuropharmacological evidence which suggests that the
(-)-isomers have a higher affinity for 5-HT2 receptors than the (+)-isomers (Lyon et
al., 1986). However, (-)-MDA produced nearly complete substitution for LSD at the
highest dose tested. This is congruent with a previous report which found that LSD
substitutes for (-)MDA (Broadbent et al., 1995).
These findings also confirm previous results obtained in our laboratory in
which the stereoisomers of MDA and MDMA produced partial substitution for mesca
line while very little amphetamine-lever responding occurred in subjects trained to dis
criminate between the two drugs and saline (Baker & Taylor, under review). How
ever, these results are incongruent with those of Young and Glennon (1993). They
demonstrated that rats can be trained to discriminate the optical isomers of MDA.
They reported that amphetamine produced (+)-MDA-appropriate responding while
DOM produced (-)-MDA-appropriate responding. In the present study, there was no
evidence to support the notion of isomeric specificity. In other words, the (+)-iso
mers were not more similar to amphetamine than the (-)-isomers. Conversely, the
stereoisomers of both drugs were more like LSD and all of the isomers produced neg
ligible amounts of amphetamine-lever responding. The stereoisomers of MOMA and
MDA produced only partial generaliz.ation of responding to the LSD-appropriate lever
and did not produce a greater percentage of such responding following the admin
istration of the high doses of any of the isomers. The highest dose of (+)-MOMA,
(-)-MDMA and (+)-MDA was behaviorally disruptive and subjects emitted only one
or two responses. Curiously, (-)-MDA (2.5 mg/kg) was not disruptive and produced
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nearly complete generalization to the LSD-appropriate lever.
In contrast to previous reports from investigations in which subjects are trained
to discriminate between amphetamine and saline (Glennon & Young, 1984; Glennon
et al.,

1988), the (+)-isomers do not appear to be amphetamine-like when subjects are

trained to discriminate a hallucinogen as well. Clearly, the extent to which the stereo
isomers are hallucinogen- or stimulant-like appears to depend on the training drugs
employed. Further, it appears that when subjects are trained to discriminate multiple
drug stimuli (e.g., with LSD and amphetamine component), drugs which are tested
for substitution that have similar components will not produce complete generalization
to either component. The present findings tend to support the human subjective
reports that MDMA and MDA produce subjective interoceptive stimuli that are similar
to both stimulants and hallucinogens but are distinct from both of these traditional drug
classes and may represent a novel therapeutic drug class named the entactogens
(Nichols et al., 1986). A three choice drug discrimination assay may provide a greater
degree of precision in which to investigate the complex discriminative stimulus proper
ties of compounds than the more traditional two choice procedure.

Appendix A
Western Michigan University Institutional
Animal Care and Use Committee
(IACUC)
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IACUC Number
Date of Receipt
Date of Approval

WESTERN l\fiCIDGAN UNIVERSITY
INSTITIJTIONAL ANIMAL CARE
AND USE COMMITTEE (IACUC)
Application to use Vertebrate Animals for Research or Teaching
The use of any vertebrate animals in research and/or teaching without prior approval of the Institutional
Animal Care and Use Committee (IACUC) is a violation of Western Michigan University policies and
procedures. This Committee is charged with the institutional responsibility for assuring the appropriate care
and treatment of vertebrate animals.
Mail 6 copies of the typed application and any supplements to Research and Sponsored Programs, Room A221 Ellsworth Hall, (616) 387-3670.
Any application that includes use of hazardous materials, chemicals, radioisotopes or biohazards must be
accompanied with SUPPLEMENT A.
Any application that includes survival surgery must be accompanied with SUPPLEMENT B.

Lisa E. Baker
Principal Investigator/Instructor

Psychology
Department

7-4484
Campus Phone

Responsible Faculty Member
(if PI not faculty member)

Department

Campus Phone

Title of Project/Course: Evaluation of MOMA and MDA stereoisomers in a three-choice drug
discrimination among a stimulant, a hallucinogen and saline.
Check One:
I.

Teaching ____

Research__X....___

Other ___________

ANIMAL USE CATEGORIES (check ONLY one category)

A.
B.

C.

__.X_._ Projects that involve little or no discomfort (including injections).
___Projects that may result in some discomfort or pain, but of short duration.
Anesthetics, analgesics or tranquilizers will be used.
___ Projects that may result in significant discomfort or pain. Anesthetics, analgesics, or
tranquilizers will not be used.
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II.

ANIMAL USE FACILITIE.S

Please indicate the building and room(s) where the animal(s) will be housed and cared for as well as the
location of the experiments and procedures if different from w here housed.
Animals will be housed and cared for in Wood Hall. room 289. The experimental procedures will be conducted in
Wood Hall, room 227.
III.

ANIMAL USE SUMMARY

In language understandable to a layperson, summarize your primary aims and describe the proposed use of
animals as concisely as possible. Bear in mind that the IACUC is primarily interested in the responsible,
necessary, humane use of animals. Include a description of procedures designed to assure that discomfort
and pain to animals will be minimized. It should include method of restraint; method of � with test
compound; and methods of euthanasia or disposition of the animal after the experiment.
This study involves a series of experiments. the primary objective of which is to further explore the stimulus effects of
MDMA and MDA stereoisomers. A brief rationale and description of the proposed experiments follow.
Some investigators have suggested that the individual stereoisomers of the designer drugs MOMA and MDA have
qualitatively distinct stimulus effects. For example. ( +) MDA is presumably more similar to the psychomotor
stimulant amphetamine. while (-) MDA is more similar to hallucinogenic substances. in particular, DOM and
mescaline (Glennon and Young, 1982; 1984). Results of our research (in particular, a series of experiments I
conducted prior to coming to WMU) are not in complete agreement with this notion. The purpose of the proposed
series of experiments is to further examine the stimulant and hallucinogenic components of the stereoisomers of
MOMA and MDA. While the majority of drug discrimination studies with these compounds have involved two lever
(dntg vs saline) discriminations. the present experiments will involve training a 3 lever (drug vs saline vs drug)
discrimination.
Discrimination Training:
Male Sprague-Dawley rats will be trained to discriminate a psychomotor stimulant (d-amphetamine OR cocaine) from
an hallucinogen (mescaline OR LSD) and from saline in a three-lever operant task. Sixteen animals will be trained to
discriminate cocaine-saline-LSD and another sixteen animals will be trained to discriminate d-amphetamine-saline
mescaline. To establish these discriminations, rats will be administered an intraperitoneal injection of one of the
training drugs or saline and placed in an operant chamber 15 min later. Reinforcers (0.1 ml sweetened condensed milk
diluted 50% in water) will be delivered for responses on the correct lever, which will vary depending on which
compound is administered. Twenty min training sessions will be conducted once per day, 6 days a week (Mon-Sat).
Drug and saline training sessions will alternate on a random basis (e.g. SSAAASSSMMMSSASMSS ..., S=saline,
A=amphetamine. M=mescaline). During training, only one drug will be administered per day. Animals may
receive a drug on an average of 4 days per week, but no animal will receive a drug for more than three consecutive
days.
Testing:
When animals have achieved the discrimination criterion (minimum 85% correct responding for 10 consecutive days),
substitution tests will begin. These tests involve administering a novel compound in place of the training drug, and
allowing the animal to complete 20 consecutive responses on either lever without reinforcement. Each of the following
compounds will be tested over a wide range of doses: ( +) MDA (0.125-1.5 mg/kg);(-) MDA (0.125-1.5 mg/kg); ( +)
MOMA (0.125-2.5 mg/kg); (-) MOMA (0.125-3.5 mg/kg). In addition, at least two lower doses of each of the training
drugs will be tested. At least three training sessions will occur between substitution tests. After these tests have been
completed, additional tests may be conducted in some animals with dopaminergic and serotonergic antagonists given
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in combination with each training drug. The antagonists consist of haloperidol (0.125 - .5 mg/kg), Sch 39166 (0.11.0), and pirenpirone (0.02 - 0.32 mg/kg).

Persons involved in animal training:

Graduate and undergraduate students who have been (and will be) trained under my supervision will be running these
experiments. Each student will run 16 animals per day. I will be responsible for overseeing that the experimental
procedures are carried out properly and directing the order of test administrations. I will also be responsible for
routine observation of each animal's health throughout the duration of these studies.

Euthanasia:

Following the completion of behavioral experiments, animals will be euthanized by CQi.
removed and preserved for later histological procedures.

Their brains may be

References:
Baker et al. (1994) Discriminative stimulus effects of the stereoisomers of 3,4-Methylenedioxymethamphetamine
(MDMA): involvement of serotonin release. submitted for review.
Glennon, R. A., Young, R., Rosecrans, J. A. and Anderson, G. M. (1982). Discriminative stimulus properties of
MDA analogs. Biological Psychimry. 17: 807-814.
Glennon R.A. and Young R. (1984). Further investigation of the discriminative stimulus properties of MDA.
Pharmacology, Biochemistry and Behavior. 20: 501-505..

IV.

JUSTIFICATION FOR ALL ANIMAL EXPERIMENTS
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Please provide a narrative with reference sources which addresses each of the following:
A.

What assurance can be provided to indicate that the procedure is not duplicative?

B.

Have non-live animal techniques (e.g. in vitro biological systems, computer simulation, audiovisual
demonstration) been considered? Explain why they have not been utilized.

I have done a fairly extensive review of the drug djscriminatjon literature, and am fairly certain no one has
conducted the experiments described in this protocol,

My research questions involve behavioral measures of drug effects, which are not possible to obtain without
live o rganisms,
C.

D.

Why has this species been selected for this procedure?

The principal investigator has extensive experience with this species in this experimental procedure.
How many animals will be used in this project? How often will its procedures be done and over what
duration?

A minimum of thirty-two animals will be used for this study Cn = 16 for each trainjng group}, Procedures will
be conducted six days a week, The estimated time to complete the study is about one year,
E.

In light of concern to minimize the number of animals used in experimentation, how will you
determine the number of animals to be used?

Sixteen animals will be trained on each of two three lever discriminations, A minimum of eight animals will be
required to complete all test sessions in order to conduct appropriate statistical tests on the data, Since these
may be difficult discriminations to learn, and since the duration of the study is fairly long, it is necessary to
train at least twice the minimum required to complete all tests, This judgment is based on my experience with
drug discrimination procedures,
F.

What is the anticipated pain or distress response of the animal; and what is the duration of discomfort?
(Injections not included.)

Minimal pain due to injections
G.

How will the pain in the animal be monitored?

N.A.

H.

What sedative, analgesic, or anesthetics will be used, if any? Include dose, route and frequency of
administration.

I.

What is the justification if pain relieving drugs are not used?

N.A
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WESTERN MICffiGAN UNIVERSITY
INVESTIGATOR IACUC CERTIFICATE
Title of Project:
Evaluation of MDMA and
among a stimulant, a hallucinogen and saline.

MDA stereoisomers in a three-choice drug discrimination

The information included in this IACUC application is accurate to the best of my knowledge. All personnel
listed recognize their responsibility in complying with university policies governing the care and use of
animals.
I declare that all experiments involving live animals will be performed under my supervision or that of
another qualified scientist. Technicians or students involved have been trained in proper procedures in
animal handling, administration of anesthetics, analgesics, and euthanasia to be used in this project.
If this project is funded by an extramural source, I certify that this application accurately reflects all
procedures involving laboratory animal subjects described in the proposal to the funding agency noted above.
Any proposed revisions to or variations from the animal care and use data will be promptly forwarded to the
IACUC for approval.

•K

___Disapproved

Approved

___Approved with the provisions listed below

/

IACUC Chairperson
Acceptance of Provisions
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Signature: Principal investigator/Instructor
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